Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Tumor necrosis factor (TNF)-alpha is a central cytotoxic and proinflammatory cytokine. Research on the benefits of TNF-alpha inhibition as a form of therapy has focused almost exclusively on autoimmune, inflammatory disorders. InflixiMAB, a chimeric antibody to human TNF-alpha, was recently approved for the management of Crohn disease and rheumatoid arthritis. The potential applications of inflixiMAB in the management of cancer are just beginning to be explored. This article reviews the biology, mechanism of action, pharmacology, and toxicity of inflixiMAB. Existing clinical experience and inflixiMAB's potential role as an immunosuppressant and antitumor agent in the management of cancer are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Shock and Tissue Injury Induced by Recombinant Human Cachectin
Tracey, K. J., Beutler, B., Lowry, S. F., Merryweather, J., Wolpe, S., Milsark, I. W., Hariri, R. J., Fahey, T. J., Zentella, A., Albert, J. D., et al. (1986) · Science · doi:10.1126/science.3764421 · Cited by 2,549
Starnes, C. O. (1992) · Nature · doi:10.1038/357011a0 · Cited by 284
Cited by
Signalling pathways of the TNF superfamily: a double-edged sword
Aggarwal, B. B. (2003) · Nature Reviews Immunology · doi:10.1038/nri1184 · Cited by 2,793
How I treat refractory acute GVHD
Deeg, H. J. (2007) · Blood · doi:10.1182/blood-2006-12-041889 · Cited by 407
TNF ligands and receptors – a matter of life and death
MacEwan, D. J. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704549 · Cited by 391
Tumor necrosis factor-α blockade for the treatment of acute GVHD
Couriel, D., Saliba, R., Hicks, K., Ippoliti, C., de Lima, M., Hosing, C., Khouri, I., Andersson, B., Gajewski, J., Donato, M., et al. (2004) · Blood · doi:10.1182/blood-2003-12-4241 · Cited by 261
Self-citationTumors and inflammatory infiltrates: Friends or foes?
Brigati, C., Noonan, D. M., Albini, A., & Benelli, R. (2002) · Clinical & Experimental Metastasis · doi:10.1023/a:1015587423262 · Cited by 230
Metadata
- Authors
- Couriel, D. R., Hicks, K., Giralt, S., & Champlin, R. E.
- Venue
- Current Opinion in Oncology
- Published
- 2000-11
- Volume
- 12
- Issue
- 6
- Pages
- 582-587
- ISSN
- 1040-8746 (ISSN-L)
- OpenAlex
- W2329873423
- Cited by
- 65
- References
- 3
- FWCI
- 6.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation. https://app.cochat.ai/papers/10.1097/00001622-200011000-00011
- The paper
- Couriel, D. R., Hicks, K., Giralt, S., & Champlin, R. E. (2000). Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation. Current Opinion in Oncology. https://doi.org/10.1097/00001622-200011000-00011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.